Survey
Quarterly Survey: Depression Bipolar Disorders and Auvelity and Caplyta
Ticker(s): ITCI, AXSMThe survey includes 20 Psychiatrists.
How many patients with Major Depressive Disorder (MMD) do you have under your care?
How many patients with Bipolar Disorder do you have under your care?
Are you familiar with Auvelity (dextromethorphan HBr-bupropion HCl) and data to date?
Are you familiar with Caplyta (lumateperone) and data to date?
How would you best describe your practice?
How many of your patients are on the following
treatments today?
- Caplyta:
- Auvelity:
- Latuda:
- Vraylar:
- Rexulti:
- Other:
How many of your patients do you consider eligible for Auvelity (dextromethorphan HBr-bupropion HCl)?
How many patients did you prescribe Auvelity to in the last 90 days ?
How many total patients do you expect prescribe Auvelity to in the next 90 days (cumulative)?
How do you expect usage of Auvelity in your patients to increase/decrease moving forward? Please be specific.
How would your rate Auvelity on the following
(where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
How many of your patients do you consider eligible for Caplyta (lumateperone)?
How many patients did you prescribe Caplyta to in the last 90 days ?
How many total patients do you expect to prescribe Caplyta to in the next 90 days (cumulative)?
How do you expect usage of Caplyta in your patients to increase/decrease moving forward? Please be specific.
How would your rate Caplyta on the following
(where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
What changes, if any, have you noticed with payor reimbursement and insurance for MDD treatments?
What changes, if any, have you noticed with payor reimbursement and insurance for Bipolar treatments?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
